

## Anika to Present at the 2017 Canaccord Genuity Musculoskeletal Conference on March 14, 2017

BEDFORD, Mass.--(BUSINESS WIRE)-- **Anika Therapeutics, Inc.** (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary **hyaluronic acid ("HA") technology**, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the 2017 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 14, 2017 at 10:00 am PT. The conference is being held at the Westin San Diego hotel.

A live audio webcast of the presentation may be accessed via the "[Investor Relations](#)" section of Anika's website at [www.anikatherapeutics.com](http://www.anikatherapeutics.com). An audio archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.

**Anika Therapeutics, Inc.** (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary **hyaluronic acid (HA) technology**. Anika's orthopedic medicine portfolio includes **ORTHOVISC®**, **MONOVISC®**, and **CINGAL®**, which alleviate pain and restore joint function by replenishing depleted HA, and **HYALOFAST®**, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit [www.anikatherapeutics.com](http://www.anikatherapeutics.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170228005073/en/>

For Investor Inquiries:

Anika Therapeutics, Inc.  
Sylvia Cheung, 781-457-9000  
Chief Financial Officer

or

For Media Inquiries:

Pure Communications, Inc.  
Katie Engleman, 910-509-3977

Source: Anika Therapeutics, Inc.

News Provided by Acquire Media

---